Femasys Inc. Obtains Medical Device Establishment License from Health Canada
August 31, 2023 08:30 ET
|
Femasys Inc.
ATLANTA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with two lead revolutionary product...
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
August 10, 2023 08:00 ET
|
Femasys Inc.
- Patient enrollment has commenced in landmark pivotal trial for lead product candidate, FemBloc® - Three product approvals achieved in Canada for FemaSeed®,...
Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc
August 03, 2023 08:45 ET
|
Femasys Inc.
ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product...
Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women
June 26, 2023 08:00 ET
|
Femasys Inc.
- Pivotal clinical trial to begin in the third quarter of 2023 - ATLANTA, June 26, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide...
Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences
June 15, 2023 08:00 ET
|
Femasys Inc.
-- Keith Kendall former President, COO and CFO of drug delivery company, Aquestive Therapeutics and Alistair Milnes COO of biotechnology company, Bicycle Therapeutics both join Femasys’ Board of...
Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023
June 14, 2023 08:00 ET
|
Femasys Inc.
ATLANTA, June 14, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include...
Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada
June 08, 2023 08:30 ET
|
Femasys Inc.
-- FemCath® is the first intrauterine catheter that allows for selective evaluation of a fallopian tube with natural saline and air contrast -- -- FemCath is used in conjunction with Femasys’ FemVue®...
Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023
May 11, 2023 16:05 ET
|
Femasys Inc.
-Received regulatory approval for both FemaSeed® and FemCerv® products from Health Canada- ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet...
Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting
May 11, 2023 08:30 ET
|
Femasys Inc.
ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include...
Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada
May 03, 2023 08:30 ET
|
Femasys Inc.
- FemCerv® is the first endocervical tissue sampler designed to collect and contain a comprehensive sample to maximize quality and quantity - ATLANTA, May 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc....